Table 1 Clinical and pathological data of patients included in TCGA-BLCA
From: HYAL3 as a potential novel marker of BLCA patient prognosis
Characteristic | Low expression of HYAL3 | High expression of HYAL3 | P |
|---|---|---|---|
n | 207 | 207 | Â |
T stage, n (%) | Â | Â | 0.504 |
 T1 | 4 (1.1%) | 1 (0.3%) |  |
 T2 | 56 (14.7%) | 63 (16.6%) |  |
 T3 | 102 (26.8%) | 94 (24.7%) |  |
 T4 | 31 (8.2%) | 29 (7.6%) |  |
N stage, n (%) | Â | Â | 0.432 |
 N0 | 128 (34.6%) | 111 (30%) |  |
 N1 | 23 (6.2%) | 23 (6.2%) |  |
 N2 | 36 (9.7%) | 41 (11.1%) |  |
 N3 | 6 (1.6%) | 2 (0.5%) |  |
M stage, n (%) | Â | Â | 0.962 |
 M0 | 103 (48.4%) | 99 (46.5%) |  |
 M1 | 5 (2.3%) | 6 (2.8%) |  |
Pathologic stage, n (%) | Â | Â | 0.143 |
 Stage I | 4 (1%) | 0 (0%) |  |
 Stage II | 59 (14.3%) | 71 (17.2%) |  |
 Stage III | 75 (18.2%) | 67 (16.3%) |  |
 Stage IV | 67 (16.3%) | 69 (16.7%) |  |
Sex, n (%) | Â | Â | 0.264 |
 Female | 60 (14.5%) | 49 (11.8%) |  |
 Male | 147 (35.5%) | 158 (38.2%) |  |
Age, n (%) | Â | Â | 0.275 |
  ≤ 70 | 123 (29.7%) | 111 (26.8%) |  |
  > 70 | 84 (20.3%) | 96 (23.2%) |  |
Histologic grade, n (%) | Â | Â | 0.662 |
 High Grade | 196 (47.7%) | 194 (47.2%) |  |
 Low Grade | 9 (2.2%) | 12 (2.9%) |  |
Subtype, n (%) | Â | Â | 0.623 |
 Non-Papillary | 140 (34.2%) | 135 (33%) |  |
 Papillary | 64 (15.6%) | 70 (17.1%) |  |
Smoker, n (%) | Â | Â | 0.894 |
 No | 56 (14%) | 53 (13.2%) |  |
 Yes | 146 (36.4%) | 146 (36.4%) |  |
OS event, n (%) | Â | Â | 0.003 |
 Alive | 131 (31.6%) | 100 (24.2%) |  |
 Dead | 76 (18.4%) | 107 (25.8%) |  |
Lymphovascular invasion, n (%) | Â | Â | 1.000 |
 No | 67 (23.7%) | 63 (22.3%) |  |
 Yes | 78 (27.6%) | 75 (26.5%) |  |
 Age, median (IQR) | 68 (59.5, 75) | 69 (61.5, 76.5) | 0.112 |